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Objectives
The European Centre for Disease Prevention and Control (ECDC) supports countries to monitor
progress in their response to the HIV epidemic. In line with these monitoring responsibilities, we
assess how, and to what extent, the continuum of care is being measured across countries.
Methods
The ECDC sent out questionnaires to 55 countries in Europe and Central Asia in 2014. Nominated
country representatives were questioned on how they defined and measured six elements of the
continuum. We present our results using three previously described frameworks [breakpoints; Joint
United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets; diagnosis and treatment
quadrant].
Results
Forty countries provided data for at least one element of the continuum. Countries reported most
frequently on the number of people diagnosed with HIV infection (37; 93%), and on the number in
receipt of antiretroviral therapy (ART) (35; 88%). There was little consensus across countries in
their approach to defining linkage to, and retention in, care. The most common breakpoint (>19%
reduction between two adjacent elements) related to the estimated number of people living with
HIV who were diagnosed (18 of 23; 78%).
Conclusions
We present continuum data from multiple countries that provide both a snapshot of care provision
and a baseline against which changes over time in care provision across Europe and Central Asia
may be measured. To better inform HIV testing and treatment programmes, standard data
collection approaches and definitions across the HIV continuum of care are needed. If countries
wish to ensure an unbroken HIV continuum of care, people living with HIV need to be diagnosed
promptly, and ART needs to be offered to all those diagnosed.
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Introduction
Interest has grown in the HIV continuum of care since
the Centers for Disease Control and Prevention (CDC)
highlighted the spectrum of engagement in HIV care in
the USA [1–4]. The continuum of care emphasizes the
importance of continuity of good-quality and accessible
HIV services so that people living with HIV experience
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long-term viral suppression. This has long-term health
benefits for the individual receiving treatment and gen-
eral public health benefits as community-level viral
suppression reduces onward viral transmission [5–9].
Several authors have reported HIV care continuum data
from European countries including Belgium [10], Denmark
and Sweden [11], France [12], Ireland [13], the Nether-
lands [14], Russia [15], Spain [16] and the UK [17]. How-
ever, issues have been raised about the utility of the HIV
continuum of care, particularly relating to cross-country
comparisons. Across countries there is no consensus as to
which elements should be included, which elements
should be compared, and how these elements should be
defined. Also, importantly, to date no analytic framework
has been agreed that allows cross-country comparison of
continuum data. Potential frameworks include breakpoints
[18], 90-90-90 targets [19], and quadrants [20].
In 2014, Raymond and colleagues presented continuum
data from several countries and analysed these data using
the concept of breakpoints in the continuum, points
where there is a large drop between successive elements
[18]. This concept was previously used to comment on
US continuum data [21], and has been referred to as
“leaks” [15,22]. Raymond and colleagues quantified the
drop needed between elements to constitute a breakpoint
as at least 19 percentage points [18].
An alternative analytic framework for continuum of
care data is the Joint United Nations Programme on HIV/
AIDS (UNAIDS) 90-90-90 targets [19]. The targets are that,
by 2020, 90% of all people living with HIV will know their
HIV status, 90% of all people with diagnosed HIV infection
will receive sustained ART, and 90% of all people receiv-
ing ART will have viral suppression [19]. These targets
relate to four elements of the HIV care continuum: the
estimated number of people living with HIV; the number
who know their HIV status; the number currently on ART;
the number with viral suppression.
Using “cut-points” of 60%, Kelly and Wilson divide
countries into quadrants based on observed data on the
number of people living with HIV who are diagnosed and
the number diagnosed on ART [20]. Quadrant 1 includes
countries with high diagnosis and treatment rates; quadrant
2 includes countries with high diagnosis rates but low
treatment rates; quadrant 3 includes countries with low
diagnosis and treatment rates; quadrant 4 includes coun-
tries with low diagnosis rates but high treatment rates.
In 2004, European and Central Asian countries adopted
the Dublin Declaration concerning the region’s response
to HIV [23]. Since 2010, the European Centre for Disease
Prevention and Control (ECDC) has supported countries to
monitor progress in implementing this declaration. There
have been three reporting rounds, in 2010, 2012 and
2014, for the region’s 55 countries [24]. In line with these
monitoring responsibilities, we assess how, and to what
extent, the HIV continuum of care is measured across
Europe and Central Asia. We also present baseline analysis
of continuum data and consider whether the three
frameworks discussed above assist the analysis and inter-
pretation of continuum data from multiple countries.
Method
A question on the HIV continuum of care was included
in the questionnaire used to measure implementation of
the Dublin Declaration in 2014. The question asked for
data on six continuum elements: the number of people
[1] living with HIV; [2] diagnosed with HIV infection [3];
linked to care [4]; retained in care [5]; on ART [6]; who
have an undetectable viral load. In December 2013, the
questionnaire was circulated in electronic (PDF) format to
nominated representatives in 55 countries. It was
requested that responses be forwarded to ECDC by the
end of March 2014. Data validation consisted of raising
data queries with country representatives directly and
sharing draft analytical outputs for comment.
Country representatives were asked to describe their
methods for defining and measuring continuum elements.
Data sources were categorized as cumulative population-
based data, annual population-based data, and cohort
studies. In our results, we summarize the data sources
used and, for each element, present examples of defini-
tions/approaches to measurement (chosen based on being
the most frequently reported, being a unique example, or
being an example that could be considered for wider
uptake across countries).
For countries reporting two or more elements, analysis
was conducted to identify and describe progression along
the care pathway. To facilitate this analysis, three frame-
works were considered: breakpoints [18], global targets
[19], and quadrant assignment [20]. A country was con-
sidered to have a breakpoint if there was a reduction of
more than 19% between two adjacent elements (there are
potentially five breakpoints in a six-point continuum). A
country was considered to be meeting one or more of the
90-90-90 targets if the percentage of people in one ele-
ment (numerator) was 90% or more of the number of
people in the preceding element (denominator). Countries
were classified into a quadrant depending on the percent-
age of people estimated to be living with HIV who had
been diagnosed and the percentage of those diagnosed
who were on treatment.
For comparative purposes, in some of our analyses we
stratify countries according to whether they were a Euro-
pean Union (EU)/European Economic Area (EEA) country
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or not. We include Switzerland in the EU/EEA group.
Results are presented as among countries for which rele-
vant information was available.
Results
Data availability
Of the 55 countries contacted, 40 (73%) provided quanti-
tative data for at least one element of the HIV continuum.
Of the 32 EU/EEA (plus Switzerland) countries contacted,
28 (88%) provided quantitative data for at least one ele-
ment, and 12 (52%) of the 23 non-EU/EEA countries con-
tacted provided data. Thirty-two (58%) of all countries
contacted provided data for at least four elements and 13
(24%) provided data for all six elements. The 13 countries
were Armenia, Austria, Azerbaijan, Bulgaria, Denmark,
Georgia, Luxembourg, the Netherlands, Romania, Serbia,
Spain, Switzerland and the United Kingdom.
Among the 40 countries providing quantitative data,
the elements most frequently reported were the number
of people diagnosed (37 countries; 93%) and the num-
ber of people on ART (35 countries; 88%) (see Fig. 1).
Of these 40 countries, 31 (77%) based their response on
cumulative population-based data, six (15%) on annual
population-based data, and three (8%) on cohort data.
Defining continuum of care elements
Countries use different definitions of continuum elements.
Although some countries do report the UNAIDS Spectrum
tool estimates of numbers of people living with HIV,
many countries reported concerns about the relevance of
these estimates for a region with concentrated and low-
level HIV epidemics. Luxembourg generated survey-based
estimates showing the percentage of people living with
HIV who knew their status. Germany reported that the
number of people living with HIV is estimated based on
symptoms and CD4 count at the time of HIV diagnosis.
Diagnosed with HIV
Seventy-five per cent (30 of 40) of countries define this
element as the cumulative number ever diagnosed. The
cumulative figure may or may not exclude persons
known to have died. In the United Kingdom, where access
to HIV care is open and free, the annual number of peo-
ple seen for HIV care was considered a proxy of the total
number of people living with diagnosed HIV.
Linked to care
Possibly reflecting diverse health systems across the
region, there was little consensus across countries in how
to define linkage to care in terms of both population and
time period. In some countries, registration was consid-
ered evidence of linkage to care. In some countries, a
diagnosed person was considered to be linked to care
only if they attended a particular type of health facility.
A specific laboratory test was considered as evidence of
linkage to care in some countries. In the United Kingdom,
a person was considered linked to care when there was
evidence of a CD4 count test result within 3 months of
diagnosis. In Spain, the time period was 6 months and in
Serbia it was 12 months.
Retained in care
In some countries, this was defined as having at least one
clinical visit per year; in others, it was defined as being in
Fig. 1 Percentage of European and Central Asian countries reporting quantitative data for different elements of the HIV continuum of care
(n = 40). ART, antiretroviral therapy; EEA, European Economic Area; EU, European Union.
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care for a certain amount of time after linkage to care (for
example, 1 year), and in some countries those retained in
care were considered a subset of those on ART. In one
country, the term was interpreted as in-patient care.
On treatment and undetectable viral load
The number of persons in receipt of ART was defined as
the number ever started on treatment or the number of
those on treatment at the end of the year or when last
seen. The cut-off level at which the virus was considered
undetectable varied across countries. Of the 25 countries
reporting data, 11 (44%) reported the threshold they used
for viral suppression. A further three countries who did
not report data also reported the threshold they used. Of
the 14 countries reporting thresholds for viral suppres-
sion, eight (57%) used <50 HIV-1 RNA copies/mL. How-
ever, countries reported a wide range of thresholds from
<20 to <500 copies/mL. Five countries reported rates of
viral suppression using at least two thresholds.
Frameworks for analysing and interpreting continuum
data
Breakpoints in the continuum
Countries most frequently reported a breakpoint between
the estimated number of people living with HIV and
those diagnosed. Of the 23 countries reporting on these
two adjacent elements, 18 (78%) reported a breakpoint >
19%. Counties least commonly reported a breakpoint
between linkage to and retention in care. Of the 22 coun-
tries providing data, only three (14%) reported a break-
point >19% between these two adjacent elements. Table 1
presents breakpoints in the HIV continuum in Europe and
Central Asia by country.
UNAIDS 90-90-90 targets
Table 2 presents country data related to 90-90-90 targets.
Sweden reported that they met all three targets, with the
UK reporting that they met two targets. Of 23 countries
providing data, three (13%) reported that > 90% of those
estimated to be living with HIV had been diagnosed. Of
33 countries providing data, two (6%) reported that
> 90% of those diagnosed with HIV were on ART, and
nine of 24 (38%) countries reported that > 90% of those
on ART were virally suppressed.
Quadrants based on numbers of people living with HIV
diagnosed and treated
Figure 2 presents countries as assigned to quadrants
depending on the percentage of people estimated to be
living with HIV who have been diagnosed and the per-
centage of those diagnosed on treatment. The figure
shows the majority of western European countries, as
well as the EU/EEA average, to be in quadrant 1 (≥60%
on both axes). In particular, Sweden stands out with 91%
reportedly being diagnosed and 92% of these being
reported to be on ART. Alongside five countries (Arme-
nia, Azerbaijan, Bulgaria, Georgia and Moldova), the
non-EU/EEA average is shown to be placed in quadrant 3
where both criteria are <60%.
Four-element continuum
As reported above, the elements with least agreement
across countries on how to define them were linkage to,
and retention in, care. Based on this finding, we present a
framework for analysing and interpreting continuum data
based on the remaining four elements (living with HIV;
diagnosed with HIV; on ART; undetectable viral load).
Sixteen countries reported data on these four elements.
Figure 3 lists the 16 countries and presents cumulative
figures for them by each of the four elements. In the 16
countries, 76% of people living with HIV had been diag-
nosed, 78% of those diagnosed were on treatment, and
88% of those on treatment were virally suppressed. Of all
people living with HIV, 53% were virally suppressed. Fig-
ure 3 shows levels of continuity of care in non-EU/EEA
countries to be lower than those in EU/EEA countries.
Discussion
The HIV continuum of care may be applied as a public
health tool to measure the effectiveness of health systems
to monitor the percentage of those diagnosed among peo-
ple living with HIV and to ensure those diagnosed are on
treatment for their own personal benefit and the public
health benefit of reducing onward transmission. In this
paper, we present evidence of how the different elements
of the HIV continuum of care are defined and measured
in Europe and Central Asia.
We present both a snapshot of care provision and a
baseline against which changes over time in care provi-
sion across Europe and Central Asia may be measured.
We also present data according to different frameworks
for analysing and interpreting the continuum of care.
Our analysis clearly identifies variation in the methods
applied to describe and measure elements, and in the
availability of data. Most countries base their figures on
population-based data, with a few using cohort studies.
The accuracy of population-based data will vary given
that they assimilate data from different sources which
may represent different collection methods and different
time periods. Cohort studies avoid some of the limitations
of population-based data but often fail to provide accu-
rate national data/estimates on the number diagnosed as,
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Table 1 Breakpoints in the HIV continuum in Europe and Central Asia by country
Country Diagnosis Linkage to care Retention in care ART Viral suppression
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kosovo
Kyrgyzstan
Latvia
Liechtenstein
Lithuania
Luxembourg
Macedonia
Malta
Moldova
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Romania
Russia
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Countries that do well in terms of ensuring a continuum of care, such as the Netherlands, Spain, Switzerland and the United Kingdom, may have a
breakpoint in diagnosing people living with HIV but once people are diagnosed they progress from one element to the next. However, in some coun-
tries, such as Azerbaijan, there are multiple breakpoints in the continuum.
Colour coding: dark grey indicates an element that is <60% of its predecessor; light grey indicates an element that is 6080% of its predecessor;
medium grey indicates an element that is >80% of its predecessor. dark and light grey correspond to Raymond’s concept of breakpoints. Grey indicates
no data reported.
ART, antiretroviral therapy.
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Table 2 How are European and Central Asian countries performing against 90-90-90?
Country Diagnosis ART
Viral
suppression
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kosovo
Kyrgyzstan
Latvia
Liechtenstein
Lithuania
Luxembourg
Macedonia
Malta
Moldova
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Romania
Russia
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
The table presents country data related to 90-90-90 targets. One country, Sweden, currently meets all three targets. The United Kingdom is meeting
two but not the one relating to the percentage of people living with HIV diagnosed.
Colour coding: dark grey indicates an element that is <70% of its predecessor; light grey indicates an element that is 7089% of its predecessor;
medium grey indicates an element that is ≥ 90% of its predecessor. Medium grey indicates that a country is meeting that element of 90-90-90. Grey
indicates no data reported.
ART, antiretroviral therapy.
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in most cases, it is not known how representative the
data are for the country as a whole. Combining cohort-
based and population-based approaches may allow trian-
gulation of data from different sources.
We report that countries were more likely to have data
on the number of people diagnosed with HIV infection
and the number of people on ART than for other contin-
uum elements. Consequently, the ECDC recently devel-
oped a tool for countries to use to estimate the number
of people living with HIV [25]. In terms of standardiza-
tion and data availability, the most problematic elements
were linked to, and retained in, care. It may be difficult
to obtain a Europe-wide definition of these elements
given the wide variations in health systems.
It should prove possible to introduce standard defini-
tions for the remaining four elements. Based on the
responses to our questionnaire, we recommend that the
number of people diagnosed be defined as the cumulative
number of people diagnosed with HIV infection less those
known to have died, and, where possible, the number
known to have left the country. The number on treatment
should be defined as those known to be on treatment at
the end of the calendar year (potentially assessed based
on date last seen for care), and 200 copies/mL should be
used as the standard threshold for viral suppression.
Variability in data availability, quality, sources and
measurement makes it difficult to compare results across
countries and between adjacent elements and ensures that
there are limitations to our analyses. Missing data
demand that caution should be exercised when interpret-
ing our results. For example, it is likely that, as a result
of missing data on one or more elements, the true num-
ber of breakpoints in the continuum will be higher than
we report. All figures were self-reported by countries and,
although some validation of data was conducted, figures
have not been fully, independently verified and are
dependent on the reliability of country systems.
As definitions, data sources and health systems differ
across countries, caution is required when comparing
data between countries and in aggregating data across
countries. Even where similar methods have been applied
across countries to measure an element, the accuracy of
the outputs may vary. For example, we show that many
countries rely on the UNAIDS Spectrum of people living
with HIV to report on this first element. It is highly likely
that the accuracy of these estimates will vary between
countries depending on the quality of data sources
Fig. 2 How are European and Central Asian countries performing in terms of ensuring people living with HIV (PLHIV) are diagnosed and trea-
ted? Quadrant 1: countries with high diagnosis and treatment rates. Quadrant 2: countries with high diagnosis rates but low treatment rates.
Quadrant 3: countries with low diagnosis and treatment rates. Quadrant 4: countries with low diagnosis rates but high treatment rates. Quad-
rants were defined following the definition of Kelly and Wilson [20]. Colour coding: light grey indicates European Union (EU) and European
Economic Area (EEA) countries plus Switzerland; dark grey indicates non-EU/EEA countries less Switzerland. The grey box denotes the countries
within quadrant 1 that are meeting the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets. ART, antiretroviral therapy.
Fig. 3 Continuum of care in 16 countries of Europe and Central
Asia. European Union (EU) and European Economic Area (EEA)
countries included: Austria, Bulgaria, Denmark, France, Germany,
Luxembourg, the Netherlands, Romania, Spain, Sweden and the
United Kingdom; non-EEA countries included: Armenia, Azerbaijan,
Georgia and Serbia. ART, antiretroviral therapy.
© 2017 The Authors.
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utilized and national HIV prevalence. Countries reporting
to the ECDC have aired concern about the relevance of
UNAIDS estimates in countries with concentrated and
low-level HIV epidemics.
In assessing whether the various frameworks assist the
analysis and interpretation of multiple country contin-
uum data, we also came across limitations. In relation to
the concept of breakpoints in the continuum, we applied
a figure of > 19% as reported by Raymond and col-
leagues[18]. This figure is somewhat arbitrary. Also some-
what arbitrary is the quadrant threshold of 60% of people
living with HIV being diagnosed and ≥ 60% of those
diagnosed being on treatment. We recommend further
analysis where different breakpoints are applied between
elements and where a higher threshold is applied across
the quadrants.
Regarding the strengths of the different frameworks,
we believe both the breakpoint and quadrant frameworks
provide a useful approach to identifying where problems
occur and where resources should be focused to improve
a country’s response to its HIV epidemic. Across coun-
tries, the most important breakpoint relates to ensuring
that people living with HIV are diagnosed. To maximize
the benefits of earlier detection (by improving a person’s
health and life expectancy through treatment) and to
minimize the risk of onward transmission (through ART
and behavioural change), it is essential that the percent-
age of people living with undiagnosed HIV who are diag-
nosed is increased in all countries. In relation to
countries in Europe and Central Asia, we believe that the
quadrant framework highlights the most important ele-
ments of the continuum, namely diagnosis and treatment,
and presents a clear and concise visual way of comparing
and contrasting country data.
Based on our analysis, we also recommend the use of
two additional frameworks for analysing continuum data.
The UNAIDS 90-90-90 targets provide a useful frame-
work for analysing a country’s continuum of care and in
providing objectives to which countries can aspire. We
present evidence for a number of countries meeting one
or more of these targets.
Having highlighted little consensus across countries in
their approach to defining linkage to, and retention in,
care, we finally recommend the use of a four-element
continuum (living with HIV; diagnosed with HIV; on
ART; undetectable viral load). This framework focuses on
those elements for which introducing standard definitions
is possible and which link to the UNAIDS 90-90-90 tar-
gets. As monitoring of quality of care is important, we
recommend that separate measures be used to monitor
the remaining two quality-of-care indicators as secondary
outcomes.
Conclusions
To better inform HIV testing and treatment programmes
across countries in Europe and Central Asia, standard
definitions of the elements in the HIV continuum of care
are needed. Many countries of the region have data on
the continuum and are able to report against its elements.
If countries wish to ensure an unbroken HIV continuum
of care, people living with HIV need to be diagnosed
promptly, and ART needs to be offered to all those diag-
nosed regardless of CD4 count in accordance with
updated World Health Organization (WHO) guidelines
[26]. It is essential that countries continue to focus on
strengthening all aspects of the continuum of care to
achieve higher rates of viral suppression, to improve care
quality for those living with HIV, and to decrease HIV
transmission risk at the population level.
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